Floatz logo

Tinodasertib

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)

EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) cohort.

Asset / SponsorPhaseRating
Nilotinib
The University of Hong Kong
Phase 2BBB
Blinatumomab
Novartis Pharmaceuticals
Phase 3BBB
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BBB
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
Imatinib
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

Tinodasertib is also rated in:

colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
leukemia, myeloid, accelerated-phaseDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →